Biological Rationale for Peripheral Blood Cell-Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer.
Giuseppe Luigi BannaAlex FriedlaenderMarco TagliamentoVeronica MollicaAlessio CortelliniSara Elena RebuzziArsela PrelajAbdul Rafeh NaqashEdouard AuclinLucia GarettoLaura MezquitaAlfredo AddeoPublished in: Current oncology reports (2022)
Inflammatory indexes based on PBC may indicate a pro-inflammatory condition affecting the immune response to cancer. The lung immune prognostic index (LIPI), consisting of derived neutrophils-to-lymphocyte ratio (NLR) and lactate dehydrogenase, is a validated prognostic tool, especially for pretreated aNSCLC patients, where the combination of NLR and PD-L1 tumour expression might also be predictive of immunotherapy benefit. In untreated high-PD-L1 aNSCLC patients, the Lung-Immune-Prognostic score (LIPS), including NLR, ECOG PS and concomitant steroids, is prognostic, and its modified version might indicate patients with favourable outcomes despite an ECOG PS of 2. NLR times platelets (i.e., SII), included in the NHS-Lung score, might improve the prognostication for combined chemoimmunotherapy. PBC-derived inflammatory indexes and related scores represent accurate, reproducible and non-expensive prognostic tools with clinical and research utility.
Keyphrases
- end stage renal disease
- peripheral blood
- advanced non small cell lung cancer
- ejection fraction
- chronic kidney disease
- newly diagnosed
- oxidative stress
- peritoneal dialysis
- squamous cell carcinoma
- poor prognosis
- clinical trial
- epidermal growth factor receptor
- patient reported outcomes
- skeletal muscle
- mass spectrometry
- young adults
- high resolution
- insulin resistance
- binding protein
- tyrosine kinase